Rethinking Peptide Cycles: What Desensitization Means

Your Receptors Are Getting Tired of You

You wouldn't max out on squats seven days a week. It's just not a sustainable way to make progress. Forum guides apply the same logic to peptides, and users commonly report that a growth hormone stack feels weaker after several weeks of daily use. How much of that is biology, and how much is expectation or product quality, is harder to say.

The usual reason given for cycling growth hormone secretagogues (GHS) is receptor desensitization. Think of it like this: your cells have receptors on their surface, waiting for a signal. When you inject something like ipamorelin, it docks with the ghrelin receptor (GHSR) and tells the pituitary to release growth hormone. In a 2004 cell study, ghrelin-activated receptors desensitized rapidly, were pulled off the cell surface within 20-60 minutes, and took about 6 hours to return. Fewer receptors mean the same dose of peptide produces a weaker signal. That's cultured cells exposed to the natural hormone, though; nobody has measured receptor numbers in people using these peptides.

It's not just at the cell surface, either. Your body is a master of homeostasis. When it senses chronically elevated levels of GH and its downstream product, IGF-1, it triggers a negative feedback loop. Your hypothalamus might produce more somatostatin (the 'off' switch for GH release) and your pituitary becomes less responsive. Cycling is meant to give both systems time to reset.

The direct human evidence is small. In a 1998 study, 12 healthy older adults injected hexarelin twice daily for 16 weeks. Their GH response fell by about 45%, then returned to baseline after 4 weeks off, so the loss was partial and reversible. MK-677, an oral ghrelin mimetic (not a peptide), looks different: in a 2-year randomized trial in 65 older adults, 25 mg once daily kept GH and IGF-1 raised for at least a year.

The Two Philosophies of Cycling

Most of the rigid, one-size-fits-all tables online aren't based on tested protocols. The schedules users describe boil down to one of two approaches.

The Time-Based Approach: Preventing Burnout

This is proactive management: breaks are built in from the start rather than added once results stall. There are two main ways users do this:

• Pulse Cycling (e.g., 5 days on / 2 days off): Users commonly describe this for long-term use of GH secretagogues, running a protocol Monday through Friday and taking the weekend off. The idea is a brief but regular break for receptors to re-sensitize. If the cell data apply, receptors return within hours, but no study has tested whether a 5/2 schedule keeps a dose effective longer than daily use.

• Block Cycling (e.g., 8-12 weeks on / 4-8 weeks off): This is the classic bulk/cut cycle approach. Users run a protocol for a couple of months toward a specific goal, then stop completely, aiming for a fuller reset of receptors and feedback loops. The hexarelin study is the closest human test: the GH response recovered after 4 weeks off. Whether that holds for other compounds hasn't been studied.

The Goal-Based Approach: The Mission Dictates the Timeline

This is simpler. The cycle lasts as long as the training goal. During a 16-week massing phase, the GHS stack runs for 16 weeks. On an 8-week cut, the peptides stop when the diet ends. Fans of this approach say it prevents running peptides aimlessly, which wastes money and, if the desensitization theory holds, blunts the response.

Not All Peptides Are Created Equal

The case for cycling applies mainly to peptides that work on the GH axis, primarily the GH secretagogues. Healing peptides are usually treated differently, although the evidence on them comes almost entirely from animals.

• Peptides Users Cycle: These are the GHS compounds. They directly stimulate a single pathway that shows signs of downregulation. This includes GHRPs (like GHRP-2, GHRP-6, hexarelin, ipamorelin) and GHRHs (like Mod GRF 1-29 and CJC-1295). Only hexarelin has direct human data on losing effect over time (see our hexarelin profile); for the others, the case rests on mechanism and user reports.

• Peptides Usually Run Without a Fixed Off Period: This category is dominated by BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4, not the full protein). They aren't thought to act through a single, easily desensitized receptor. In rodent and cell studies, BPC-157 has been linked to angiogenesis (blood vessel formation) via VEGFR2 and nitric oxide signaling, and it increased growth hormone receptor expression in rat tendon cells. As of October 2026, human BPC-157 data are limited to three small uncontrolled pilots, and FDA says it has found no human exposure data for the TB-500 fragment. Users run these until the injury is healed or progress plateaus, so cycle length follows recovery rather than receptor fatigue: about 4 weeks for a minor strain, 12 for a nagging tendon, in forum reports. No study has checked whether either loses effect with continuous use, so 'no off period needed' is a community convention, not a tested finding.

Building a Strategic Cycle: Sample Protocols

These are frameworks from community guides and vendor material, not tested protocols, and the doses are reports, not recommendations. Our dosing protocols overview compares community numbers with trial doses.

What We Still Don't Know

• Whether most GHS peptides lose effect in people. The hexarelin study had 12 participants, and we found no long-term human data on repeated ipamorelin, GHRP-2, GHRP-6 or Mod GRF 1-29 use.
• How long a break needs to be. Cell data point to hours, the hexarelin study to 4 weeks or less, and community guides to 4-8 weeks.
• Whether the drop-off users notice is biological. If a GHS stack isn't providing the same sleep quality or recovery in week 10 that it did in week 2, that's a reasonable signal. It hasn't been checked against blood GH or IGF-1, though, and product quality varies between vials. Our article on long-term effects of peptide use covers what extended use may do to the endocrine system.